Welcome to our dedicated page for Seer news (Ticker: SEER), a resource for investors and traders seeking the latest updates and insights on Seer stock.
Seer, Inc. (Nasdaq: SEER) is a life sciences company focused on deep, unbiased proteomics, and the SEER news feed reflects that focus. Company press releases highlight how Seer’s Proteograph Product Suite—combining proprietary engineered nanoparticles, automation instrumentation, consumables, and analytical software—is being used in large-scale and translational research across cardiovascular disease, oncology, aging biology, and other areas of human health.
Investors and researchers following SEER news will find regular updates on financial results, platform launches, and scientific validation. Seer’s quarterly earnings announcements describe revenue from Proteograph instruments, consumable kits, and Technology Access Center service projects, along with commentary on adoption of its platform and the growth of third-party publications and preprints that use its technology.
The news stream also covers Seer’s presence at major scientific and investor conferences. Releases detail presentations at meetings such as the Human Proteome Organization World Congress and the American Society of Human Genetics, where independent and collaborative studies showcase applications of the Proteograph platform in deep plasma proteomics, biomarker discovery, proteogenomics, and multi-omic precision medicine research. Other items include participation in healthcare and life sciences investor conferences, as well as board and governance updates.
For those tracking how proteomics technologies are being deployed in population-scale and translational studies, Seer’s news provides insight into collaborations, such as population-scale proteomics projects and genome-wide association studies using the Proteograph platform. Bookmarking the SEER news page offers a centralized view of Seer’s financial disclosures, scientific milestones, and corporate developments as reported in its official communications.
Seer, Inc. (Nasdaq: SEER) reported Q1 2021 financial results, revealing a revenue decrease to $62,000 from $177,000 in Q1 2020, attributed to diminished activity linked to an NIH grant. The company's operating expenses surged to $16.6 million, a significant rise from $6.0 million the previous year, mainly due to increased employee costs and product development expenses. The net loss widened to $16.4 million compared to $5.5 million in the prior year. The company maintained a robust cash position of approximately $531 million as of March 31, 2021.
Seer, a life sciences company known for its innovative proteomics platform, announced participation in the BofA Securities 2021 Healthcare Conference. The event will take place virtually on May 13 at 10:15 a.m. PT and will feature a fireside chat with management. Investors can access the live webcast through the Investor section of Seer’s website, with an archived replay available afterward. Seer's Proteograph Product Suite offers advanced, unbiased proteomic analysis, designed for use in various laboratories.
Seer, a life sciences company, will report its Q1 2021 financial results after the market closes on May 10, 2021. The management team will host a conference call starting at 1:30 p.m. PT / 4:30 p.m. ET. Investors can access the live audio webcast on Seer’s website, with an archived replay available post-event. Seer's focus is on advancing proteomics through its Proteograph™ Product Suite, designed for deep, unbiased analysis in life sciences research.
Seer has entered a non-exclusive agreement with SCIEX to combine their technologies, enhancing proteomics workflows for diverse laboratories. This partnership integrates SCIEX's mass spectrometry with Seer's Proteograph Product Suite, facilitating unbiased and deep proteomics studies at scale. The Proteograph system, featuring engineered nanoparticles and advanced automation, aims to accelerate research by providing comprehensive protein analysis with unprecedented sensitivity and speed. Both companies anticipate future collaborations to further innovate in proteomics.
Seer, Inc. (Nasdaq: SEER) reported financial results for the year and fourth quarter ended December 31, 2020. Revenue surged to $656,000, up from $116,000 in 2019, driven by grants and collaboration studies. However, operating expenses rose sharply by 102% to $34.3 million, leading to a net loss of $32.8 million. Seer announced significant partnerships, including with the Salk Institute and SCIEX, while strengthening its balance sheet with $417.5 million in net proceeds from its IPO and follow-on offering. The company is transitioning to the second phase of its commercialization plan.
Seer, Inc. (Nasdaq: SEER) announced it will report its financial results for Q4 and full year 2020 on March 29, 2021, after market close. The company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET, available for live audio on their Investor website. Seer specializes in proteomics and is developing the Proteograph Product Suite, aimed at revolutionizing biological information analysis for life sciences research. The product suite operates efficiently and is not intended for diagnostics.
Seer, a life sciences company listed on Nasdaq under the symbol SEER, will participate in the Cowen 41st Annual Healthcare Conference on March 3, 2021. The management will engage in a fireside chat at 8:40 a.m. PT / 11:40 a.m. ET. A live webcast will be accessible on the company’s investor website, with an archived replay available post-conference. Seer focuses on enhancing scientific outcomes through its Proteograph™ Product Suite, designed for comprehensive proteomics analysis in a short time frame.
Seer, Inc. (Nasdaq: SEER) has appointed Deep Nishar and Dr. Mostafa Ronaghi to its Board of Directors, effective February 13, 2020. Nishar, a Senior Managing Partner at SoftBank, has extensive experience in tech companies such as Google and LinkedIn. Dr. Ronaghi is a former CTO of Illumina and co-founder of Grail. Their appointments aim to enhance Seer’s leadership in the proteomics field, promoting innovative approaches to biological insights and market expansion. The company's Proteograph™ Product Suite aims to provide deep, unbiased proteomics analysis, advancing scientific outcomes.
Seer, a life sciences company, announced the closing of a public offering of 3,750,000 shares of Class A common stock at $67.00 per share, generating $251.25 million before commissions. In this offering, Seer sold 1,650,000 shares while 2,100,000 shares were sold by existing stockholders. The offering was managed by J.P. Morgan, Morgan Stanley, BofA Securities, and Cowen. The SEC approved the offering on January 27, 2021. The funds raised will be used to enhance Seer's proteomics platform, including the Proteograph Product Suite.
Seer, a life sciences company, has announced a public offering of 3,750,000 shares of Class A common stock at $67.00 per share. The offering includes 1,650,000 shares from Seer and 2,100,000 from selling stockholders. There is a 30-day option for underwriters to purchase an additional 562,500 shares. The offering is expected to close around February 1, 2021. Major investment banks involved are J.P. Morgan, Morgan Stanley, BofA Securities, and Cowen. Seer will not receive proceeds from selling stockholders' shares.
FAQ
What is the current stock price of Seer (SEER)?
What is the market cap of Seer (SEER)?
